A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for EGFR
mutation-positive lung cancer.
The drugs involved in this study are:
- EGF816
- Gefitinib